MedTrace Logo

A First-in-Human PoC Study With BEN2293 in Patients With Mild to Moderate Atopic Dermatitis

NCT04737304 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 123

Last updated 2023-06-18

No results posted yet for this study

Summary

A randomised, adaptive design, double-blind, placebo-controlled, first-in-human, two-part study to investigate the safety, tolerability, PK and preliminary efficacy of multiple topical doses of BEN2293 in patients with mild to moderate AD.

Conditions

Interventions

DRUG

BEN2293 (0.25% or 1.0% w/w) or matching placebo

BEN2293 and placebo will be administered as a topical ointment. Both ointments contain the same excipients; placebo ointment has been manufactured in the same way except for the addition of 0.25% and 1.0% (w/w) BEN2293.

Sponsors & Collaborators

  • BenevolentAI Bio

    lead INDUSTRY

Principal Investigators

  • Alexander Thompson, MBBS · MAC Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-14
Primary Completion
2023-01-12
Completion
2023-01-26

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04737304 on ClinicalTrials.gov